trial

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

NCTId NCT07185815
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Recruiting
Enrollment 24 (estimated)
Sponsored by Mapi Pharma Ltd.
Primary completion 2026-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Recruiting
Enrollment
24 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2025-08-01
Primary completion
2026-12-31
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)

Sponsors

Mapi Pharma Ltd.Lead Sponsor

Sites

6 total
Ahmedabad, IndiaAhmedabad, IndiaBeersheba, IsraelNess Ziona, IsraelRamat Gan, IsraelTel Aviv, Israel

Linked catalysts

1
Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Actin — primary completion2026-12-31

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE1,PHASE2
Primary Completion Date
2026-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
lead_sponsor
Mapi Pharma Ltd.
company
indication
Major Depressive Disorder
indication
Depressive Disorder, Major
indication
Bipolar I Disorder
indication